15070-84-5

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
5-AMINO-1-(3-CHLORO-PHENYL)-1 H-PYRAZOLE-4-CARBOXYLIC ACID is utilized as a pharmaceutical intermediate for the development of drugs with various therapeutic applications. Its pyrazole structure and functional groups contribute to its potential as an antimicrobial, antitumor, and antiviral agent, making it a valuable compound in the discovery and synthesis of new medications.
Used in Organic Synthesis:
In the field of organic synthesis, 5-AMINO-1-(3-CHLORO-PHENYL)-1 H-PYRAZOLE-4-CARBOXYLIC ACID serves as a building block for the creation of more complex organic compounds. The presence of the carboxylic acid group allows for further chemical reactions and modifications, facilitating the synthesis of a wide range of molecules with potential applications in various industries.

Upstream product

• 2312-23-4 m-chlorophenylhydrazine hydrochloride 
• 15001-08-8 5-amino-1-(3-chlorophenyl)-1H-pyrazole-4-carboxylic acid,ethyl ester 

Relevant academic research and scientific papers

Synthesis of pyrazole-carboxamides and pyrazole-carboxylic acids derivatives: Simple methods to access powerful building blocks

Hybrid systems containing pyrazole moiety show a wide spectrum of biological activities. To access novel hybrids with pyrazole ring, in this work we synthesized twenty pyrazole-carboxylic acids and twenty pyrazole-carboxamides, using simple synthetic methods, to be used as building blocks in the development of new structures.

Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups

Factor XIa (FXIa) inhibitors are promising novel anticoagulants, which show excellent efficacy in preclinical thrombosis models with minimal effects on hemostasis. The discovery of potent and selective FXIa inhibitors which are also orally bioavailable has been a challenge. Here, we describe optimization of the imidazole-based macrocyclic series and our initial progress toward meeting this challenge. A two-pronged strategy, which focused on replacement of the imidazole scaffold and the design of new P1 groups, led to the discovery of potent, orally bioavailable pyridine-based macrocyclic FXIa inhibitors. Moreover, pyridine-based macrocycle 19, possessing the phenylimidazole carboxamide P1, exhibited excellent selectivity against relevant blood coagulation enzymes and displayed antithrombotic efficacy in a rabbit thrombosis model.

NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS

The present invention provides compounds of Formula (Ia): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.